Drugs / Probiotic 6600
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07047339 | Jul 2025 → Jul 2026 overdue | colitis | Changhai Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Probiotic 6600 | “Probiotic 6600 capsules are enteric capsules” NCT07047339 ↗ |
| Known as | Probiotics 6600 | “Drug: Probiotics 6600” NCT07047339 ↗ |
| Modality | Other / unclassified | “As the core commensal bacteria of human body, probiotic 6600 has a unique ability to synthesize adhesins and exopolysaccharides.” NCT07047339 ↗ |
| Route | Oral | “taken orally twice a day (after meals in the morning and evening)” NCT07047339 ↗ |